| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | CFO &Cbo
1 company
Rajavelu Esther is a See Remarks at SPRO. Recent filings cover 0 purchases and 8 sales. Those positions are worth an estimated $2.5M at current prices.
Our model assigns Rajavelu Esther a below-average insider score of 32/100, based on 7 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -91.4%.
Rajavelu Esther's largest disclosed position is in SPRO as See Remarks, worth about $2.5M. The recent filings there lean toward selling, a net 233,154 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | SPRO Spero Therapeutics, Inc. | See Remarks | Sell | 25,240 | $2.51 | $63,352.40 | -2.5% | -54.0% | - | |
| Feb 6, 2026 | SPRO Spero Therapeutics, Inc. | See Remarks | Sell | 87,917 | $2.36 | $207,484.12 | -8.0% | +3.7% | - | |
| Feb 2, 2026 | SPRO Spero Therapeutics, Inc. | See Remarks | Sell | 18,442 | $2.20 | $40,572.40 | -1.6% | +12.1% | - | |
| Nov 7, 2025 | SPRO Spero Therapeutics, Inc. | See Remarks | Sell | 40,270 | $2.37 | $95,439.90 | -4.4% | -6.5% | - | |
| Feb 5, 2025 | SPRO Spero Therapeutics, Inc. | CFO &Cbo | Sell | 20,689 | $0.78 | $16,137.42 | -2.8% | -32.7% | +162.3% | |
| Nov 8, 2024 | SPRO Spero Therapeutics, Inc. | CFO &Cbo | Sell | 40,596 | $1.31 | $53,008.31 | -9.7% | -34.6% | +86.4% |